Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Treatment of MDS/AML Patients With an Impending Hematological Relapse With Azacitidine Alone or in Combination With PEvonedistat - a Randomized Phase 2 Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04712942
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:37.442386+00:00
Published At
2023-08-21T00:00:00+00:00
Record Updated At
2023-08-21
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myeloid Leukemia in Remission", "Myelodysplastic Syndromes", "Minimal Residual Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-08-21"
protocolSection.identificationModule.nctId
"NCT04712942"
protocolSection.identificationModule.officialTitle
"Treatment of MDS/AML Patients With an Impending Hematological Relapse With Azacitidine Alone or in Combination With PEvonedistat - a Randomized Phase 2 Trial"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Myeloid Leukemia in Remission (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Minimal Residual Disease (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.